Results 241 to 250 of about 1,116,836 (319)

Rapid, In Situ and Non‐Destructive Analysis for the Evaluation of Microplastics Degradation in Water Via Haze Measurement

open access: yesChemistry–Methods, EarlyView.
Haze measurements were used to demonstrate the photocatalytic degradation of polystyrene and polymethylmethacrylate microplastics. Indeed, considering that after the degradation the amount of the particles will decrease and the shape will change, the haze will change and can be used as a validation of the degradation.
Rossella Greco   +6 more
wiley   +1 more source

Pharmacokinetics and Safety Evaluation of a New Generic Sitafloxacin: A Phase I Bioequivalence Study in Healthy Chinese Participants

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Sitafloxacin is a new antibiotic drug belonging to the fourth generation quinolone antibiotics. The aim of this study was to evaluate the pharmacokinetics (PK), safety profiles, and bioequivalence of test and reference 50‐mg sitafloxacin tablets under fasting and fed conditions.
Yongfang Lei   +13 more
wiley   +1 more source

A Western-Style Diet Influences Ingestive Behavior and Glycemic Control in a Rat Model of Roux-en-Y Gastric Bypass Surgery. [PDF]

open access: yesJ Clin Med
Hoornenborg CW   +7 more
europepmc   +1 more source

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez   +5 more
wiley   +1 more source

Evaluation of exposure‐response‐safety relationship of model‐informed low‐dose 500 mg abiraterone acetate in prostate cancer patients

open access: yes
Cancer Communications, EarlyView.
Edmund Chiong   +15 more
wiley   +1 more source

First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract RBN‐3143 is an inhibitor of PARP14 in development for inflammatory diseases. Multiple assessments were conducted to evaluate the clinical pharmacology properties of RBN‐3134. A randomized, double‐blind, placebo‐controlled study assigned healthy volunteers (HVs) to single ascending doses (SADs) (25‐1000 mg) or multiple ascending doses (MADs ...
Thomas M. Polasek   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy